71831-21-5

Usage

Uses

Used in Pharmaceutical Industry:
4-Bromo Methylbenzyl Alcohol is used as an intermediate in the synthesis of various pharmaceutical compounds. Its unique chemical structure allows for the creation of new drug molecules with potential therapeutic applications.
Used in Perfume Industry:
In the perfume industry, 4-Bromo Methylbenzyl Alcohol is used as a fragrance ingredient. Its aromatic properties contribute to the development of complex and long-lasting scents in perfumes and other fragranced products.
Used in Chemical Industry:
4-Bromo Methylbenzyl Alcohol serves as a key intermediate in the production of various chemical compounds. Its versatility in chemical reactions makes it a valuable component in the synthesis of a wide range of products, from dyes to agrochemicals.
It is important to handle 4-Bromo Methylbenzyl Alcohol with care, as it may cause skin, eye, and respiratory irritation if not properly managed.

Upstream product

• 2417-72-3 Methyl 4-(bromomethyl)benzoate 
• 589-29-7 p-xylylene glycol 
• 51359-78-5 4-(bromomethyl)benzaldehyde 
• 99-94-5 p-Toluic acid 
• 99-75-2 4-methyl-benzoic acid methyl ester 
• 6232-88-8 4-bromomethylbenzoic Acid 

Downstream Products

• 105183-16-2 1-(4-hydroxymethyl-benzyl)-8,15,22-trimethyl-1,8,15,22-triazonia-tricyclo(13.13.6.6^8,22)tetracontane tetracation 
• 127056-29-5 C₅₉H₁₁₄N₄O⁽⁴⁺⁾ 
• 144852-56-2 {4-[4-(4-Hydroxymethyl-benzylsulfanylmethyl)-benzylsulfanylmethyl]-phenyl}-methanol 
• 144852-55-1 (4-{4-[4-(4-Hydroxymethyl-benzylsulfanylmethyl)-benzylsulfanylmethyl]-benzylsulfanylmethyl}-phenyl)-methanol 
• 1053243-19-8 (3aS,4R,8R,8aS)-5,7-Bis-(4-hydroxymethyl-benzyl)-2,2-dimethyl-4,8-bis-pyridin-4-ylmethyl-hexahydro-1,3-dioxa-5,7-diaza-azulen-6-one 
• 1054623-02-7 (4R,5S,6S,7R)-1,3-Bis-(4-hydroxymethyl-benzyl)-4,7-diisobutyl-5,6-bis-(2-trimethylsilanyl-ethoxymethoxy)-[1,3]diazepan-2-one 
• 1054606-49-3 (4R,5S,6S,7R)-4,7-Bis-cyclohexylmethyl-1,3-bis-(4-hydroxymethyl-benzyl)-5,6-bis-(2-trimethylsilanyl-ethoxymethoxy)-[1,3]diazepan-2-one 
• 1054644-41-5 (4R,5S,6S,7R)-4,7-Bis-(4-fluoro-benzyl)-1,3-bis-(4-hydroxymethyl-benzyl)-5,6-bis-(2-trimethylsilanyl-ethoxymethoxy)-[1,3]diazepan-2-one 
• 1053638-80-4 (4R,5S,6S,7R)-4,7-Bis-(3,4-difluoro-benzyl)-1,3-bis-(4-hydroxymethyl-benzyl)-5,6-bis-(2-trimethylsilanyl-ethoxymethoxy)-[1,3]diazepan-2-one 
• 1054619-94-1 (4R,5S,6S,7R)-1,3-Bis-(4-hydroxymethyl-benzyl)-4,7-bis-(4-methoxy-benzyl)-5,6-bis-(2-trimethylsilanyl-ethoxymethoxy)-[1,3]diazepan-2-one 
• 439691-96-0 [4-(azidomethyl)phenyl]methanol 
• 939378-19-5 1-bromomethyl-4-(tert-butyloxymethyl)benzene 
• 125320-20-9 4-(bromomethyl)-t-butyldimethylsilyloxymethylbenzene 
• 61-82-5 3⁽⁵⁾-amino-1,2,4-triazole 

Relevant academic research and scientific papers

A novel versatile precursor suitable for 18F-radiolabeling via “click chemistry”

As an effort to improve 18F-radiolabeling of biomolecules in method robustness and versatility, we report the synthesis and radiolabeling of a new azido precursor potentially useful for the so-called “click reaction,” in particular the ligand-free version of the copper(I)-catalyzed alkyne-azide cycloaddition. The new azido precursor may help to overcome problems sometimes exhibited by most of the currently used analogues, as it is safe to handle and it displays long-term chemical stability, thus facilitating the development of new radiolabeling procedures. Moreover, the formed 18F-labeled 1,2,3-triazole is potentially metabolically stable and could enhance the in vivo circulation time. The above azido precursor was successfully radiolabeled with 18F, with 51% radiochemical yield (nondecay-corrected). As a proof of concept, the 18F-labeled azide was then tested with a suitable alkyne functionalized aminoacid (l-propargylglycine), showing 94% of conversion, and a final radiochemical yield of 27% (>99% radiochemical purity), nondecay-corrected, with a total preparation time of 104?minutes.

New ferrocenyl P,O ligands with polar substituents

A new ferrocenyl P,O ligand has been synthesized and successfully used in the Suzuki-Miyaura coupling reaction of phenylboronic acid with bromobenzene. Some analogues carrying charged (imidazolium) or neutral (monomethylether PEG 750, tetraethylbisphospho

Reaction of Diisobutylaluminum Borohydride, a Binary Hydride, with Selected Organic Compounds Containing Representative Functional Groups

The binary hydride, diisobutylaluminum borohydride [(iBu)2AlBH4], synthesized from diisobutylaluminum hydride (DIBAL) and borane dimethyl sulfide (BMS) has shown great potential in reducing a variety of organic functional groups. This unique binary hydride, (iBu)2AlBH4, is readily synthesized, versatile, and simple to use. Aldehydes, ketones, esters, and epoxides are reduced very fast to the corresponding alcohols in essentially quantitative yields. This binary hydride can reduce tertiary amides rapidly to the corresponding amines at 25 °C in an efficient manner. Furthermore, nitriles are converted into the corresponding amines in essentially quantitative yields. These reactions occur under ambient conditions and are completed in an hour or less. The reduction products are isolated through a simple acid-base extraction and without the use of column chromatography. Further investigation showed that (iBu)2AlBH4 has the potential to be a selective hydride donor as shown through a series of competitive reactions. Similarities and differences between (iBu)2AlBH4, DIBAL, and BMS are discussed.

PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE

The present invention provides a compound represented by formula [I] shown below or a pharmaceutically acceptable salt thereof that has an inhibitory effect on 20-HETE producing enzyme. (in formula [I] above, the structure represented by formula [II] below: represents any of the structures represented by formula group [III] below: R1, R2, R3, and R4 independently represent a hydrogen atom, a fluorine atom, methyl, or the like, R5 represents any of the structures represented by formula group [IV]:

Sustainable organophosphorus-catalysed Staudinger reduction

A highly efficient and sustainable catalytic Staudinger reduction for the conversion of organic azides to amines in excellent yields has been developed. The reaction displays excellent functional group tolerance to functionalities that are otherwise prone to reduction, such as sulfones, esters, amides, ketones, nitriles, alkenes, and benzyl ethers. The green nature of the reaction is exemplified by the use of PMHS, CPME, and a lack of column chromatography.

Discovery of novel 3-(hydroxyalkoxy)-2-alkylchromen-4-one analogs as interleukin-5 inhibitors

A series of novel chromen-4-one analogs 9a-d and 10a-u was designed, synthesized and evaluated for their IL-5 inhibitory activity. Most of the chromen-4-one analogs showed strong inhibitory activity in low micro molar potency. Among them, 5-(cyclohexylmet

NOVEL 3-(4(BENZYLOXY)PHENYL)HEX-4-INOIC ACID DERIVATIVE, METHOD OF PREPARING SAME AND PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING METABOLIC DISEASE INCLUDING SAME AS EFFECTIVE INGREDIENT

The present invention relates to a novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative, a preparation method thereof, and a pharmaceutical composition comprising the same as an active ingredient for the prevention and treatment of metabolic disease. The novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention has excellent activities of activating GPR40 protein and promoting insulin secretion accordingly but has no toxicity when co-administered with other drugs. That is, the novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention can be co-administered with other drugs and can promote the activation of GPR40 protein significantly, so that the composition comprising the same as an active ingredient can be efficiently used as a pharmaceutical composition for the prevention and treatment of metabolic disease such as obesity, type I diabetes, type II diabetes, incompatible glucose tolerance, insulin resistance, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia, and syndrome X, etc.

Synthesis of dihydropyrimidine α,μ3-diketobutanoic acid derivatives targeting HIV integrase

The synthesis and antiviral evaluation of a series of dihydropyrimidinone and thiopyrimidine derivatives bearing aryl α,γ-diketobutanoic acid moiety are described using the Biginelli multicomponent reaction as key step. The most active among 20 synthesized novel compounds were 4c, 4d and 5b, which possess nanomolar HIV-1 integrase (IN) stand transfer (ST) inhibition activities. In order to understand their mode of interactions within the IN active site, we docked all the compounds into the previously reported X-ray crystal structure of IN. We observed that compounds 4c, 4d and 5b occupied an area close to the two catalytic Mg2+ ions surrounded by their chelating triad (E221, D128 and D185), DC16, Y212 and the β-diketo acid moiety of 4c, 4d and 5b chelating Mg2+. As those compounds lack anti-HIV activities in cell, their prodrugs were synthetized. The prodrug 4c′ exhibited an anti-HIV activity of 0.19 μM in primary human lymphocytes with some cytotoxicity. All together, these results indicate that the new analogs potentially interact within the catalytic site with highly conserved residues important for IN catalytic activity.

THERAPEUTIC INHIBITORY COMPOUNDS

The invention provides compounds of Formula I and Formula II: A-B-C-D-E-F-G-J (I) C-D-E-F-G-J (II) wherein A, B, C, D, E, F, G, and J have any of the values defined in the specification, and salts thereof. The compounds are useful for inhibiting plasma kallikrein, and for treating a disease or condition in an animal where inhibition of plasma kallikrein is indicated.

Polyvinylpyrrolidone-bromine complex: An efficient polymeric reagent for selective preparation of benzyl bromides in the presence of hexamethyldisilane

Benzylic bromides were conveniently obtained in high yields via the reaction of the corresponding alcohols with crosslinked polyvinylpyrrolidone- bromine complex (PVPP-Br2)/hexamethyldisilane in chloroform at reflux condition. Selective conversion of benzyl alcohol to benzyl bromide in the presence of primary aliphatic alcohols, e.g. 2-phenylethanol was also achieved.